In an era of continuous advancements in medical technology, Edwards Lifesciences (NYSE: EW), a global leader in patient-focused innovations for structural heart disease, has announced a significant ...

The recent EARLY TAVR trial (Evaluation of TAVR Compared to Surveillance for Patients With Asymptomatic Severe Aortic Stenosis) investigated the effect of early intervention with transcatheter aortic ...